Ask about this productRelated genes to: Abra antibody
- Gene:
- ABRA NIH gene
- Name:
- actin binding Rho activating protein
- Previous symbol:
- -
- Synonyms:
- STARS
- Chromosome:
- 8q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-02-02
- Date modifiied:
- 2015-04-29
Related products to: Abra antibody
Related articles to: Abra antibody
- Editor-in-Chief's Note: On September 27, 2025, ANNA and ASN collaborated on a one-day meeting at ANNA's Nephrology Nursing Summit to bring nurses and physicians together to discuss important issues in nephrology. This article is based on the panel discussion on home dialysis that focused on how innovative solutions as well as best practices can enhance patient care, improve outcomes, and reduce health care burden, while also fostering a collaborative approach between nurses and physicians. The recorded version of the panel discussion is available in ANNA's Online Library (https://library.annanurse.org/p/s/home-dialysis-26207). - Source: PubMed
Abra GrahamLiu FrankTodd LucyFreiberger LouisaFoster-Smith Leah - This Journal club evaluates recent evidence on the role of blood eosinophil count (BEC) as a biomarker to guide therapy in patients with acute exacerbations of COPD and asthma. The review focuses on three studies with different methodological approaches: a biomarker-directed corticosteroid trial (Bafadhel ., 2012), an acute biologic therapy trial using benralizumab (ABRA, 2025) and a long-term biologic therapy trial using mepolizumab (COPD-HELP, 2025). The biomarker-directed corticosteroid study demonstrated non-inferior symptom improvement while reducing steroid exposure, highlighting the potential to personalise therapy based on BEC. The ABRA trial showed that a single injection of benralizumab reduced treatment failure, prolonged time to exacerbation and improved symptom scores in patients with high eosinophils. By contrast, the COPD-HELP trial found no significant effect of mepolizumab on readmission or mortality, despite substantial eosinophil reduction. Limitations include small sample sizes, heterogeneous populations and reliance on surrogate end-points in some studies. These findings support the use of BEC-guided therapy in acute settings but suggest that long-term biologic treatment post-exacerbation may not improve hard outcomes. Future research should focus on precision medicine strategies targeting eosinophilic exacerbations and identifying patient subgroups who benefit most from biomarker-guided interventions. - Source: PubMed
Publication date: 2026/04/14
Godallage Anuradha NalikaAfrose DilValizadeh MelikaBeech AugustaJensen Jens-Ulrik SSivapalan Pradeesh - Oral Submucous Fibrosis (OSMF) is a significant global oral health problem, particularly prevalent in India, with a high risk of progression to Oral Squamous Cell Carcinoma (OSCC). This study investigates the molecular mechanisms involved in the transformation of OSMF to OSCC using transcriptomic profiling. High-throughput RNA sequencing was performed on fresh de novo OSCC samples ( = 8) and OSMF derived OSCC using Illumina-compatible NEXTflex Rapid Directional RNA Sequencing. Normalization and differential gene expression analysis were conducted, and genes exhibiting an absolute log2 fold change of ≥2 with a co-variate-adjusted -value ≤ 0.05 were identified as significant. Upregulated genes were associated with cytokine and immune responses (ABRA, TTTY14, EIF1AY), cellular proliferation and apoptosis (LINC00314, RPS4Y1, SERPINA5, TRIM63, FABP7), and energy metabolism, indicating metabolic adaptations during malignant progression. Pathway analysis showed increased expression of TNNT1, TNNI1, MYL4, and ACTN3, implicating muscle development and embryonic pathways in OSMF transformation. Conversely, genes related to epithelial differentiation and keratinization (FLG, FLG2, HRNR, TCHH, KRT73), immune regulation and tumor suppression (HLA-G, UNC5D), and metabolic signaling were downregulated, reflecting loss of tissue integrity and immune control. OSMF-derived OSCC exhibits a distinct transcriptomic landscape compared with de novo OSCC, characterized by altered epithelial differentiation, immune modulation, and activation of developmental pathways. The observed gene dysregulation findings establish that OSCC developing in the background of OSMF is molecularly distinct from de novo OSCC, underscoring the biological impact of the pre-existing fibrotic milieu on tumor transcriptional architecture. - Source: PubMed
Publication date: 2026/03/10
Prasad KavithaSamudrala Venkatesiah SowmyaAugustine DominicAnand Ananya AnuragKaryala PrashanthiDasharathy SukeerthiRao Roopa SChaki Soma - - Source: PubMed
Publication date: 2026/03/25
El Shamy OsamaSparks Matthew AShah Ankur DBermudez MariaSalani MeghaAbra GrahamStern LaurenCollins AshtéAggarwal VikramRivara Matthew BShen Jenny IBerns Jeffrey S - An 82-year-old woman presented with a rapidly progressive decline in cognitive function, which had previously been worsening over several months. Brain MRI revealed a lesion predominantly involving the leptomeninges of the right parietal lobe. Based on the presence of leptomeningeal-predominant lesions, cerebral microbleeds, and superficial siderosis, amyloid β-related angiitis (ABRA) was suspected. However, due to atypical findings such as dural enhancement, we performed a brain biopsy, leading to a definitive diagnosis of ABRA. Steroid therapy resulted in improvements in both clinical symptoms and imaging findings. Imaging findings in this case suggest that inflammation originating in the leptomeninges extended bidirectionally into both the brain parenchyma and the dura mater. This progression pattern is of particular interest for understanding the pathophysiology of ABRA and may offer a future possibility of avoiding brain biopsy by identifying characteristic imaging features. - Source: PubMed
Publication date: 2026/03/14
Imamura DaichiIshii JunkoHosoki SatoshiMiyata MayukoHara ShigeoKawamoto Michi